Boehringer Ingelheim

This was an early safety study to find the highest tolerable dose of a new drug called BI 765883 for adults with advanced pancreatic cancer. Participants received the drug either alone or combined with standard chemotherapy. The main goals were to check for side effects and see i…

This early-stage study tested a single inhaled dose of an experimental gene therapy called BI 3720931 in adults with cystic fibrosis who cannot use standard CFTR modulator drugs. The goal was to see if the treatment was safe and if it could improve lung function. The trial was te…

This study tested whether a medicine called spesolimab could help people with Netherton syndrome, a rare and severe genetic skin disorder. Participants aged 12 and older received either spesolimab or a placebo injection for 4 months, after which everyone could receive the active …

This study followed people with hidradenitis suppurativa (HS) who had already participated in earlier spesolimab trials. Researchers wanted to understand how well patients tolerate the medication and whether it continues to help control their HS symptoms over about two years. Par…

This study followed people with palmoplantar pustulosis (a chronic skin condition causing painful blisters on hands and feet) who had benefited from spesolimab treatment in earlier trials. The goal was to understand the long-term safety of monthly spesolimab injections over up to…

This study tested whether adding a new oral drug, BI 706321, to a standard Crohn's treatment (ustekinumab) could better control gut inflammation. About 50 adults with moderate to severe Crohn's disease were randomly assigned to take either the new drug or a placebo pill alongside…

This study aimed to collect real-world safety and effectiveness data on Pradaxa pellets, a blood thinner medication, for children under 12 years old with blood clots. It observed children in routine medical care who were already prescribed the medication to treat a clot or preven…

This study tested if a new drug called Avenciguat, taken alone or with an existing diabetes drug (empagliflozin), could reduce high blood pressure in the main vein leading to the liver. It involved 90 adults with liver cirrhosis from hepatitis B, hepatitis C, or fatty liver disea…

This study tested whether a new drug called BI 765845 could help reduce the amount of permanent damage to the heart muscle after a heart attack. About 160 adults who had just suffered a heart attack were randomly assigned to receive either the new drug or a placebo (dummy treatme…

This study tested if a new oral medicine called Avenciguat could safely reduce high blood pressure in the main vein leading to the liver (portal hypertension) in adults with compensated cirrhosis. About 80 participants were randomly assigned to take one of two doses of the drug o…

This study tested an oral medicine called BI 1839100 to see if it could reduce chronic cough in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). About 85 participants were randomly assigned to receive either the study drug at different dose…

This study aimed to collect real-world information about how Netherton Syndrome naturally progresses over time. Researchers planned to observe 12 patients with this rare genetic skin condition for up to 52 weeks, measuring their symptoms without providing any treatment. The goal …

This early-stage study aims to understand how a new drug called BI 1839100 is absorbed, processed, and eliminated by the body. It involves a small group of healthy male volunteers. Researchers will track the drug's path by measuring how much appears in blood, urine, and feces aft…

This early-stage study aimed to check the safety and see how the experimental drug BI 706321 moves through the bodies of healthy Japanese and Chinese men. The trial was terminated and did not test the drug for any specific disease. It involved 48 healthy male volunteers to gather…

This early-stage study aimed to check the safety and see how the body processes a new drug called BI 3731579. It involved 30 healthy adults who took the drug for 15 days. The main goal was to see what side effects occurred and to measure the drug's levels in the blood. The trial …

This was an early, basic science study to understand how a new drug candidate, called BI 1819479, is absorbed, broken down, and eliminated by the body. It involved a small group of healthy male volunteers and used tiny amounts of a radioactive form of the drug to track its path. …

This study aimed to understand the relationship between changes in lung function and changes in symptoms like cough and shortness of breath. It observed 88 patients in Greece with connective tissue disease-related progressive lung scarring who were already prescribed the drug nin…

This early, terminated study aimed to understand how two experimental cancer drugs travel to and collect in tumors. It involved 8 patients with advanced lung or head/neck cancers. Researchers used a special radioactive tracer and PET scans to take pictures showing where the drugs…